SCHEMBL739902

SCHEMBL739902

COc1cccc(C(C)(C)NC(=O)c2cc3c(NC(=O)c4ccc(CN5CCOCC5)cc4)n[nH]c3s2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
TP53 P04637 2/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
ABL1 P00519 2/20 0.54
BCR P11274 2/20 0.54
HIF1A Q16665 2/20 0.47
EPAS1 Q99814 2/20 0.47
AURKA O14965 3/20 0.46
TSHR P16473 2/20 0.45
KDM4E B2RXH2 3/20 0.45
MAPT P10636 2/20 0.45
HSD17B10 Q99714 1/20 0.45
KCNH2 Q12809 1/20 0.44
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
GALR3 O60755 1/20 0.43
FGFR1 P11362 1/20 0.43
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL740798 0.94 ABL1 (0.59) LMNASMN1; SMN2TP53NPC1RAB9A
SCHEMBL742323 0.94 ABL1 (0.61) LMNASMN1; SMN2TP53NPC1RAB9A
SCHEMBL743126 0.93 ABL1 (0.62) LMNASMN1; SMN2TP53NPC1RAB9A
SCHEMBL740986 0.93 ABL1 (0.54) LMNASMN1; SMN2TP53NPC1RAB9A
SCHEMBL742258 0.91 ABL1 (0.65) LMNASMN1; SMN2NPC1RAB9AABL1
SCHEMBL742340 0.90 ABL1 (0.55) LMNASMN1; SMN2TP53NPC1RAB9A
SCHEMBL738756 0.90 AURKA (0.55) LMNAABL1BCRAURKAMAPT
SCHEMBL740827 0.87 ABL1 (0.51) LMNASMN1; SMN2TP53NPC1RAB9A
SCHEMBL739685 0.87 ABL1 (0.56) LMNASMN1; SMN2TP53NPC1RAB9A
SCHEMBL743418 0.86 ABL1 (0.60) LMNASMN1; SMN2NPC1RAB9AABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138217-B2 Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-03-20 US claimed
US-8138217-B2 Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-03-20 US disclosed